Registered business · FR · Founded 2005 · Accounts through 2024 · Updated Jul 28, 2026
No public value estimate is available for this company yet. Review the registered details, express interest or claim the profile as the owner.
Is this your company? Claim and manage this profile
THERAVECTYS is flagged as asset-heavy or real-estate related. A public EBITDA multiple can misstate value unless assets, debt, leases and property context are reviewed first.
Create a free account to add verified turnover, normalised EBITDA, debt and one-offs for THERAVECTYS in a private workspace.
We keep this public page conservative, so weak filings never become a false price.The page can still show filed facts, but the automatic public range is blocked when those facts would make the multiple misleading.
THERAVECTYS is a business in NACE sector 72.19 based in France. The company was founded in 2005.
THERAVECTYS is listed in French National Business Register (RNE/INPI) under registry number 482324282. The public employee band is 11, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Companies in this NACE 72.19 band file annual accounts with INPI.
The most recently filed revenue (2024) stands at €253,195.
The most recent annual filing covers 2024 (period end 2024-12-31).
If you are researching THERAVECTYS for acquisition, investment, or due-diligence purposes, this page consolidates firmographics, filed accounts and the reason a public valuation curve is not shown yet.
Register your interest privately. Upswitch reviews every request and keeps it queued until a safe, verified owner contact route is available.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Claim this companyPublic regulator-filed figures across 7 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202431 Dec 2024 | €253,195 | - | €12,362,647 | €11,301,070 | - |
| 202331 Dec 2023 | €127,219 | - | €16,244,556 | €15,329,961 | - |
| 202231 Dec 2022 | €1,010,000 | - | €18,415,079 | €17,161,298 | - |
| 202131 Dec 2021 | €55 | - | €20,776,127 | €19,613,257 | - |
| 202031 Dec 2020 | €114,301 | - | €23,254,688 | €20,221,576 | - |
| 201731 Dec 2017 | €136,250 | - | €13,042,826 | €8,271,976 | - |
| 201631 Dec 2016 | - | - | €15,685,286 | €7,995,486 | - |
THERAVECTYS was founded in 2005 and is registered with French National Business Register (RNE/INPI).
THERAVECTYS is registered under NACE 72.19. That places the business within the French cluster for this activity.
The most recently filed annual accounts cover fiscal year 2024 (period end 2024-12-31), publicly available via French National Business Register (RNE/INPI).
This page shows official or licensed public company facts and valuation-readiness context for THERAVECTYS; it does not show an automated public valuation range. The available facts may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
Indicative public valuation range based on financial year 2024. This historical record does not yet contain an immutable calculation snapshot, so no sector range is reconstructed after the fact. Not a transaction value, asking price or fairness opinion.
